Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-24-095489
Filing Date
2024-08-12
Accepted
2024-08-12 16:30:24
Documents
72
Period of Report
2024-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q clsd-20240630.htm   iXBRL 10-Q 1372165
2 EX-10.1 clsd-ex10_1.htm EX-10.1 17662
3 EX-10.2 clsd-ex10_2.htm EX-10.2 110532
4 EX-31.1 clsd-ex31_1.htm EX-31.1 13930
5 EX-31.2 clsd-ex31_2.htm EX-31.2 13661
6 EX-32.1 clsd-ex32_1.htm EX-32.1 9056
7 GRAPHIC img142401494_0.jpg GRAPHIC 110228
  Complete submission text file 0000950170-24-095489.txt   7028755

Data Files

Seq Description Document Type Size
8 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT clsd-20240630.xsd EX-101.SCH 1181594
74 EXTRACTED XBRL INSTANCE DOCUMENT clsd-20240630_htm.xml XML 1000774
Mailing Address 900 NORTH POINT PARKWAY SUITE 200 ALPHARETTA GA 30005
Business Address 900 NORTH POINT PARKWAY SUITE 200 ALPHARETTA GA 30005 678-270-3631
Clearside Biomedical, Inc. (Filer) CIK: 0001539029 (see all company filings)

EIN.: 452437375 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-37783 | Film No.: 241197195
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)